Navigation Links
Editor-in-Chief of Elsevier's Epilepsy & Behavior presented with Ambassador for Epilepsy Award
Date:9/8/2011

NEW YORK, September 8, 2011 /PRNewswire/ --

Elsevier, world-leading provider of scientific, technical and medical information products and services, is pleased to announce Dr. Steven Schachter, Editor-in-Chief of Elsevier's journal Epilepsy & Behaviour, has been awarded the prestigious Ambassador for Epilepsy Award by the International Bureau for Epilepsy (IBE) and the International League against Epilepsy (ILAE) at the 29th International Epilepsy Congress in Rome in August.


In response Dr. Schachter said, "I am proud that so many members of the Editorial Board of Epilepsy & Behavior past and presenthave been recognized by the ILAE and IBE for their global contributions to epilepsy, and am privileged to work closely with them to further advance the understanding of the behavioral aspects of epilepsy and the care of patients."

This award is a lifetime honor given to individuals recognizing outstanding personal contributions to international epilepsy research and awareness. The awardees receive a scroll signed by the president of both the IBE and ILAE together with a simple pin bearing a candle, one of the enduring symbols of epilepsy. Also recognized in this year's awards were: Dr. Andres Kanner, who serves on the Editorial Board of Epilepsy & Behavior, and Dr. Asla Pitkanen, Co-Editor-in-Chief of Elsevier's journal Epilepsy Research.

The award, bestowed by ILAE and IBE every two years, is highly treasured by each person who receives them as it reflects peer recognition of their achievements at an international level.  Currently serving Epilepsy & Behavior Editors and Editorial Board Members who have received the Ambassador for Epilepsy Award include:

Dr. Steve Schachter - USA (2011)
Dr. Andres Kanner - USA (2011)
Prof. Anne Berg - USA (2009)
Dr. Gregory Holmes - USA (2007)
Prof. Christian Elger - Germany (2005)
Prof. Meir Bialer - Israel (2001)
Dr. Robert Fisher - USA (2001)
Prof. Gus Baker - UK (1999)
Prof. Ann Jacoby - UK (1999)
Prof. Martin Brodie - UK (1995)
Dr. Joyce Cramer - USA (1995)
Dr. Pavel Mares - Czech Republic (1995)
Dr. Michael Trimble - UK (1993)
Prof. Albert Aldenkamp - Netherlands (1991)
Dr. Frederic Andermann - Canada (1989)
Dr. Simon Shorvon - UK (1987)
Dr. Dieter Schmidt - Germany (1983)

About Epilepsy & Behavior
Epilepsy & Behavior is the fastest-growing international epilepsy journal.  Launched 11 years ago, it is uniquely devoted to the rapid dissemination of the most current information available on the behavioral aspects of seizures and epilepsy. Epilepsy & Behavior presents original peer-reviewed articles based on laboratory and clinical research. Topics are drawn from a variety of fields, including clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging.

Epilepsy & Behavior publishes papers on the study of:

  • • Localization of ictal and postictal behaviors
  • • Neuroendocrine aspects of epilepsy
  • • Psychiatric and psychosocial aspects of epilepsy
  • • Behavioral aspects of epilepsy surgery
  • • Cognitive and affective effects of seizure treatment
  • • Functional imaging
  • • Animal models

For more information visit: http://www.elsevier.com/locate/yebeh

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Fran Webb
Marketing Communications Manager, Elsevier
+ 44(0)1865-843244
f.webb@elsevier.com



'/>"/>
SOURCE Elsevier
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
2. NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
3. Topiramate Exposure and Birth Defect Data to be Presented at the 29th International Epilepsy Congress
4. Texas Childrens Hospital Pioneers Use of MRI-guided Laser Surgery for Revolutionary New Epilepsy Treatment
5. Upsher-Smith Laboratories Begins Phase III Study of Intranasal Midazolam for Rescue Treatment of Seizure Clusters in Epilepsy Patients
6. Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
8. Biopharma Company UCB Unveils 40 Deserving 2010 Family Epilepsy Scholarship Recipients
9. The Epilepsy Drug Market Will Remain Relatively Flat Through 2019 as Generic Erosion, Especially Within the Second-Generation Antiepileptic Drug Class, is Offset by the Launch of New Therapies
10. Cyberonics Announces Epilepsy Technology Agreements
11. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International ... promote standards of excellence for the field of eating disorders, announces the opening ... 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
Breaking Medicine News(10 mins):